60 Degrees Pharmaceuticals, Inc. (SXTP) · Nov 20, 2026 · Delisting

60 Degrees Nasdaq delisting notice forces another reverse split

Delisting notice — Bid price below $1.00 for 30 consecutive business days; suspension set for December 1 absent appeal

60 Degrees Pharmaceuticals received a Nasdaq delisting determination and is pursuing an appeal plus another reverse split to stay listed.

60 Degrees is a small specialty-pharma company selling FDA-approved ARAKODA for malaria prevention while trying to expand tafenoquine into babesiosis and other infectious-disease indications. Its financial cushion is thin: cash was $306,191 at September 30, 2026, versus $1.51 million at year-end 2025.

The Nasdaq problem has moved from warning to formal delisting action. The company failed the $1.00 minimum-bid rule for 30 straight business days, and Nasdaq staff determined it is ineligible for the normal compliance period because it already completed reverse splits within the prior year. 〔0〕

The immediate fix is defensive, not operational progress. 60 Degrees has requested a hearing and paid the $20,000 fee, which temporarily stays the suspension, but it now needs Nasdaq approval and another reverse split to preserve its listing. The proposed December 2 split is intended only to lift the quoted share price; it does not improve the company's cash position, product demand, clinical evidence, or regulatory status. 〔1〕

This matters more because the company is already dependent on external capital. The latest quarterly filing had warned that another failure to maintain Nasdaq compliance could reduce liquidity and make it harder to raise funds, while also noting equity had fallen close to Nasdaq's separate $2.5 million requirement. The filing itself also makes clear that neither the hearing nor the reverse split is assured: 〔2〕

Bottom line: This is a meaningful setback to the financing and market-access side of 60 Degrees' story, even though its drug-development plans are unchanged. The company is not yet delisted, but staying on Nasdaq now depends on a hearing outcome and a third recent reverse-split response to the same underlying weakness.

What to watch next

Nasdaq Hearings Panel decision; reverse split expected December 2

Original filing on SEC EDGAR

More 60 Degrees Pharmaceuticals, Inc. news

60 Degrees Nasdaq delisting notice forces another reverse split | SXTP Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.